Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva shares plummet amid CEO departure and bribery reports
Teva CEO Rejects Netanyahu Plea to Salvage Jerusalem Plant - Bloomberg
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - BNN Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Actavis CEO: Teva-Mylan deal could be "value-destroying" - Globes
Teva Negotiating Sale of Remaining Women's Health Assets, Report Says | Ctech
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
The Difficulties of Cloning a CEO - Bloomberg
Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Shows Progress on Restructuring But Investors Want More - TheStreet
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Teva CEO Vigodman Steps Down After Poor Outlook for 2017 | Fortune
Teva makes $40.1 billion takeover bid for Mylan | Mint
Teva to Pay $85 Million Settlement in Oklahoma Opioid Case - Bloomberg
